Latest Articles
NICE approves first immunotherapy combination for endometrial cancer - NICE website
NICE approves first immunotherapy combination for endometrial cancer NICE website
Published: Aug. 5, 2025, 11 p.m.
Optimizing Therapy for MMR-Proficient Endometrial Cancer - OncLive
Optimizing Therapy for MMR-Proficient Endometrial Cancer OncLive
Published: July 31, 2025, 2:27 p.m.
Lenvatinib Plus Pembrolizumab Versus Chemotherapy in Advanced Endometrial Cancer: Efficacy and Safety Insights - Cureus
Lenvatinib Plus Pembrolizumab Versus Chemotherapy in Advanced Endometrial Cancer: Efficacy and Safety Insights Cureus
Published: July 30, 2025, 7:21 a.m.
B7-H4 Targeting Therapies Market Growth Set to Accelerate Across the 7MM During the Study Period (2025-2040) with Advances in Immunotherapy | DelveInsight - The Malaysian Reserve
B7-H4 Targeting Therapies Market Growth Set to Accelerate Across the 7MM During the Study Period (2025-2040) with Advances in Immunotherapy | DelveInsight The Malaysian Reserve
Published: July 24, 2025, 10:55 p.m.
Stem cell therapy found to boost fertility in women with ovarian failure - Contemporary OB/GYN
Stem cell therapy found to boost fertility in women with ovarian failure Contemporary OB/GYN
Published: July 23, 2025, 6:23 p.m.
Parexel Supports GLP-1 Trials for Metabolic Disorders as Eisai Investigates Dual-Mechanism Therapy for Endometrial Carcinoma - geneonline.com
Parexel Supports GLP-1 Trials for Metabolic Disorders as Eisai Investigates Dual-Mechanism Therapy for Endometrial Carcinoma geneonline.com
Published: July 18, 2025, 11:05 a.m.
Exploring the Promise of E7386 and Lenvatinib Combination Therapy in Endometrial Carcinoma - PharmExec
Exploring the Promise of E7386 and Lenvatinib Combination Therapy in Endometrial Carcinoma PharmExec
Published: July 18, 2025, 10:08 a.m.
Eisai Explores Novel Dual Mechanism Therapy for Advanced Endometrial Carcinoma - PharmExec
Eisai Explores Novel Dual Mechanism Therapy for Advanced Endometrial Carcinoma PharmExec
Published: July 17, 2025, 10:09 a.m.
Advanced Ovarian and Endometrial Cancers Respond to Combination Immunotherapy - Labroots
Advanced Ovarian and Endometrial Cancers Respond to Combination Immunotherapy Labroots
Published: July 14, 2025, 10 a.m.
Dostarlimab Plus Chemo Prolongs Time to First, Second Subsequent Therapy Regardless of Age in Endometrial Cancer - OncLive
Dostarlimab Plus Chemo Prolongs Time to First, Second Subsequent Therapy Regardless of Age in Endometrial Cancer OncLive
Published: July 11, 2025, 6:17 p.m.
Link copied to clipboard!